Current ACC Guidelines for Hypertension Treatment
The 2025 ACC/AHA guidelines recommend a universal blood pressure treatment goal of <130/80 mm Hg for all adults, with pharmacologic therapy initiated at BP ≥130/80 mm Hg in patients with established cardiovascular disease or 10-year ASCVD risk ≥7.5%, and at BP ≥140/90 mm Hg in lower-risk individuals. 1
Blood Pressure Categories and Diagnosis
The ACC/AHA maintains the following BP classification system:
- Normal: <120/<80 mm Hg
- Elevated: 120-129/<80 mm Hg
- Stage 1 Hypertension: 130-139/80-89 mm Hg
- Stage 2 Hypertension: ≥140/≥90 mm Hg
These categories must be confirmed with averaged readings from at least two separate occasions, not single measurements. Out-of-office BP monitoring (home or ambulatory) should be obtained to confirm office readings and exclude white coat hypertension. 2
When to Start Medication: Risk-Based Algorithm
Immediate Pharmacologic Therapy (BP ≥130/80 mm Hg):
- Established cardiovascular disease
- 10-year ASCVD risk ≥7.5% using PREVENT equations (updated from 10% threshold in 2017)
- Age ≥65 years
- Diabetes mellitus
- Chronic kidney disease
Critical update: The 2025 guideline introduces the race-free PREVENT equations and lowers the risk threshold from 10% to 7.5%, substantially expanding treatment eligibility particularly among younger adults (30-60 years) and those with obesity. 1, 3
Delayed Pharmacologic Therapy (BP ≥140/90 mm Hg):
- Lower-risk individuals without the above conditions
- Exception: For secondary stroke prevention in drug-naïve patients, initiate at BP ≥140/90 mm Hg even if high-risk 2
Lifestyle Modification Only:
- Stage 1 hypertension (130-139/80-89 mm Hg) without high-risk features
- Elevated BP (120-129/<80 mm Hg)
- Consider medication if lifestyle changes prove insufficient after trial period 1
First-Line Drug Selection
For patients without compelling indications, use agents from these four classes:
- Thiazide-type diuretics (chlorthalidone preferred over hydrochlorothiazide)
- Calcium channel blockers (CCBs)
- ACE inhibitors
- Angiotensin receptor blockers (ARBs)
Never combine ACE inhibitors with ARBs - this is potentially harmful. 4
Combination Therapy Strategy
Stage 2 Hypertension (≥140/90 mm Hg):
Start with two-drug combination therapy when BP is >20/10 mm Hg above goal. Use agents with complementary mechanisms:
- ACE inhibitor or ARB + CCB, OR
- ACE inhibitor or ARB + thiazide diuretic, OR
- CCB + thiazide diuretic
Single-pill combinations improve adherence but many US formulations contain hydrochlorothiazide at suboptimal doses rather than chlorthalidone used in landmark trials - this is an important caveat. 4
Stage 1 Hypertension:
Single-agent therapy acceptable initially, but most patients ultimately require combination therapy for adequate control.
Race-Specific Considerations (Updated 2025)
The 2025 guideline removes race-based drug selection recommendations. Previously, the ACC/AHA recommended thiazide diuretics or CCBs as initial therapy for Black patients, but this race-based approach has been eliminated in favor of individualized selection based on comorbidities and response. 1
For context, the 2017 guideline specifically recommended combination therapy for Black patients with a thiazide-type diuretic or CCB. 4
Treatment Targets
General Population:
BP <130/80 mm Hg for all adults if tolerated 4
Preferred Target (New in 2025):
BP <120/80 mm Hg in selected high-risk patients who can tolerate intensive lowering without adverse effects. This represents a significant shift toward more aggressive control in appropriate candidates. 1, 5
Older Adults (≥65 years):
Systolic BP <130 mm Hg if tolerated, noninstitutionalized, ambulatory, and community-dwelling. No specific diastolic target provided. 4, 2
Patients with High Comorbidity Burden:
For those requiring institutional care or with limited life expectancy, treatment decisions should be based on clinical judgment, patient preference, and team-based risk/benefit assessment rather than rigid targets. 4
Escalation Protocol
If BP remains above target on initial therapy:
- Dual therapy → Add second agent from different class
- Triple therapy → Add third agent (typically ACE inhibitor/ARB + CCB + thiazide diuretic)
- Resistant hypertension → Add spironolactone or other agent (α-blocker, β-blocker), consider specialist referral 4
Follow-Up Intervals
- Normal BP: Reassess in 1 year
- Lifestyle modification only: 3-6 months
- After starting medication: 1 month initially, then 3-6 months once goal achieved 4, 6
Key Pitfalls to Avoid
Measurement errors: Most BP measurement errors bias readings upward, leading to overdiagnosis and overtreatment. Use proper technique with validated devices. 2
Cuffless devices: Avoid relying on smartwatches or other cuffless devices for BP management - they lack sufficient precision and reliability. 1
Single office readings: Always confirm with multiple readings and out-of-office monitoring before diagnosing hypertension.
Suboptimal diuretic dosing: Many single-pill combinations contain inadequate thiazide doses compared to trial evidence. 4
Ignoring home BP monitoring: Combined with multidisciplinary team-based care using standardized protocols, home monitoring significantly improves control rates. 1
Clinical Impact of 2025 Updates
The 2025 guideline substantially expands treatment eligibility: among the 180 million US adults not currently treated, 18.4% (33.2 million) now qualify for immediate medication, with an additional 10.8% (19.4 million) considered for treatment if lifestyle modification fails. Among 58 million adults already treated, 59.8% don't meet the <130/80 goal, and an additional 17.6% are newly eligible for intensification if pursuing the preferred <120/80 target. 3
The overarching principle: High blood pressure is the most prevalent and modifiable cardiovascular risk factor. The 2025 ACC/AHA guidelines prioritize earlier intervention, more aggressive targets in appropriate patients, and systematic implementation of team-based care to improve population-level BP control and reduce cardiovascular morbidity and mortality. 1